Cocrystal Pharma Inc（COCP）财务数据COCPCocrystal Pharma Inc

Evaluating the bottom line, Cocrystal Pharma Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3032.38%, while the net margin is -3013.33%. These profitability ratios, combined with a Return on Equity (ROE) of -311.68%, provide a clear picture of how effectively COCP converts its operational activities into shareholder value.

In the context of the broader market, COCP competes directly with industry leaders such as KYNB and TXMD. With a market capitalization of $19.83M, it holds a leading position in the sector. When comparing efficiency, COCP's gross margin of 100.00% stands against KYNB's -81.45% and TXMD's 100.00%. Such benchmarking helps identify whether Cocrystal Pharma Inc is trading at a premium or discount relative to its financial performance.

Cocrystal Pharma has not generated revenue in the previous quarters, with total revenue of $0 for Q4 2024 through Q3 2025. The gross margin for Q1 2026 is 100%, but this is against a backdrop of significant losses and negative earnings per share (EPS) of -0.17.